In a pilot study, investigators identified infection-causing agents by sequencing microbial DNA in patient blood samples.
Based on data from more than 6,000 clinical cases, the investigators from Switzerland advocated for an expansion of NIPT to cover additional alterations and associated phenotypes.
The company's assay relies on proprietary methods of DNA isolation that enable analysis of cell-free DNA from finger-stick volume blood samples.
A New York University team used its maximum-depth sequencing method for profiling rare mutations in Escherichia coli in an unbiased manner.
The company plans to offer a test that analyzes genome-wide sequencing data using a machine learning engine to detect and characterize early cancers.
The company said it plans to publish its findings on its early-detection cancer tests, and will work with CMS and the FDA on pre-market review.
The funding will support development of tests that detect cell-free DNA methylation patterns indicative of disease in specific tissues of the body.
Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining.
A prospective study used droplet digital PCR to search for treatment-informative EGFR and KRAS mutations in cell-free DNA from non-small cell lung cancer patients.
In Nature this week: transcriptomic and epigenomic analysis of bat wing development, and more.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.